|
(Health-NewsWire.Net, July 31, 2015 ) Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015
RnRMarketResearch.com Adds “Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015” which provides an overview of the Attention Deficit Hyperactivity Disorder therapeutic pipeline.
This report gives broad information on the medicinal change for Attention Deficit Hyperactivity Disorder (ADHD), complete with close examination at diverse stages, therapeutics assessment by drug target, instrument of action (MoA), course of association (RoA) and molecule sort, nearby latest overhauls, and highlighted news and press releases. It moreover reviews key players included in the remedial progression for Attention Deficit Hyperactivity Disorder (ADHD) and novel components on late-stage and halted assignments.
The report updates decision making limits and help to make capable counter philosophies to build high ground. It braces R&D pipelines by recognizing new targets and MOAs to make first-in-class and best-in-class things.
Complete report on H1, 2015 Pipeline Review of “Attention Deficit Hyperactivity Disorder” addition with 58 market data tables and 16 figures, spread across 182 pages is http://www.rnrmarketresearch.com/attention-deficit-hyperactivity-disorder-adhd-pipeline-review-h1-2015-market-report.html .
This report highlights examination al drugs from across over globe covering more than 20 treatment regions and around 3,000 proofs. The report is built using data and information sourced from our prohibitive databases, Company/University locales, SEC filings, money related authority presentations and highlighted press releases from association/school destinations and industry-specific outcast sources, set up together by our gathering. Pharmaceutical profiles/records highlighted in the report encounters incidental updation taking after a stringent course of action of methodology that ensures that each one of the profiles are upgraded with the latest plan of information. Also, techniques including live news & courses of action taking after, project based prepared box and clinical trials registries taking after insurance that the most recent enhancements are gotten on a nonstop start.
Companies Discussed/Mentioned in this Research:
Alcobra Ltd, Amarantus Bioscience Holdings, Inc., Arbor Pharmaceuticals, LLC., Cerecor Inc., Collegium Pharmaceutical, Inc., Curemark, LLC, DURECT Corporation, Eli Lilly and Company, H. Lundbeck A/S, Hisamitsu Pharmaceutical Co., Inc., Integrative Research Laboratories Sweden AB, Intra-Cellular Therapies, Inc., KemPharm, Inc., Merck & Co., Inc., Mnemosyne Pharmaceuticals, Inc., Neos Therapeutics, Inc., NeuroDerm Ltd., Otsuka Holdings Co., Ltd., P2D Bioscience, Polleo Pharma Limited, Reviva Pharmaceuticals Inc., Samyang Biopharmaceuticals Corporation, Shire Plc, Signature Therapeutics, Inc, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Tris Pharma, Inc. and Vernalis Plc
Drugs Profile Discussed in this Research :
(nicotine + opipramol hydrochloride), amfetamine XR, AR-08, BLI-1008, BNC-375, brexpiprazole, centanafadine IR, centanafadine SR, CM-4612, CTX-1301, CTX-1302, dasotraline, dextroamphetamine, dextroamphetamine MR, Drug for Attention Deficit Hyperactivity Disorder, edivoxetine, eltoprazine, etiguanfacine, guanfacine hydrochloride ER, HTL-1071, IRL-752, ITI-214, KP-415 CR, lisdexamfetamine dimesylate, Metadoxine ER, methylphenidate, methylphenidate hydrochloride, methylphenidate hydrochloride, methylphenidate hydrochloride SR, methylphenidate hydrochloride XR, MGS-0028, molindone hydrochloride ER, PBF-509, PD-2005, PD-2007, PFR-08001, PFR-8026, RP-5063, SHP-465, Small Molecule for ADHD, Small Molecules for Attention Deficit Hyperactivity Disorder, Small Molecules to Agonize NMDA2D for ADHD, Small Molecules to Antagonize H3 Receptor for ADHD And Alzheimer's Disease, Small Molecules to Inhibit COMT for Cognitive Disorders, Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders, Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD, Small Molecules to Modulate Choline Transporter for ADHD, TAK-137, TRI-102, V-81444, viloxazine hydrochloride, vortioxetine hydrobromide
Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=397265 . (This is a premium report price at US$2000 for a single user PDF license)
Scope :
• The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy :
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Neurology Therapeutics Market.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
